For survival and functional recovery, spinal anesthesia for hip-fracture surgery is not superior to general anesthesia, researchers reported on Oct. 9 in the NEJM/New England Journal of Medicine…. read more.
New research published in Anaesthesia (a journal of the Association of Anaesthetists) by researchers from the University of Bristol can help to improve the efficiency of surgery and help tackle… read more.
Medtronic plc announced it has received CE (Conformité Européenne) Mark for the Hugo robotic-assisted surgery (RAS) system, authorizing the sale of the system in Europe. CE Mark approval… read more.
COVID-19 infection linked to increased risk of dangerous blood clots during surgery PrintEmail App Venous thromboembolism (VTE) is a condition in which dangerous blood clots form in the… read more.
By developing the first statistical model to finely characterize how ketamine anesthesia affects the brain, a team of researchers at MIT’s Picower Institute for Learning and Memory and… read more.
A new adhesive that mimics the sticky substance barnacles use to cling to rocks may offer a better way to treat traumatic injuries. Inspired by the sticky substance… read more.
Immune cells called natural killer cells contribute to organ rejection after transplantation because they miss “self” proteins on donor cells, according to a study appearing in an upcoming… read more.
When prescribed following outpatient surgery, nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen provide better pain control with less side-effects than the opioid codeine. Researchers reported these findings on June… read more.
Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.
PAION AG announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved Byfavo (remimazolam besylate) in adults for procedural sedation. Byfavo is an ultra-short-acting intravenous… read more.
Merck has announced that the FDA has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous… read more.
Liminal BioSciences Inc. announced that the FDA has approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
